Role of radiofrequency ablation in unresectable hepatocellular carcinoma: An Indian experience
| Autor: | Ajay Duseja, Radha K. Dhiman, Yogesh Chawla, Niranjan Khandelwal, Naveen Kalra, Virendra K. Arya, Mandeep Kang, Arvind Rajwanshi, Anmol Bhatia |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
RFA
medicine.medical_specialty Radiofrequency ablation R895-920 unresectable law.invention Lesion Medical physics. Medical radiology. Nuclear medicine law Ascites medicine Vascular and Interventional Radiology Mini Symposia Radiology Nuclear Medicine and imaging Hemoperitoneum HCC Prospective cohort study Survival rate Survival analysis business.industry small medicine.disease Surgery Hepatocellular carcinoma Radiology medicine.symptom business |
| Zdroj: | The Indian Journal of Radiology & Imaging Indian Journal of Radiology and Imaging, Vol 23, Iss 02, Pp 139-144 (2013) |
| ISSN: | 0971-3026 |
| Popis: | Aims: To evaluate the role of radiofrequency ablation (RFA) as an ablative technique in patients with unresectable hepatocellular carcinoma (HCC). Settings and Design: A tertiary care center, prospective study. Materials and Methods: The subjects comprised 31 patients (30 males, one female; age range 32-75 years) with HCC (41 lesions) who were treated with image-guided RFA. The follow-up period ranged from 3 months to 6 years, and included a multiphasic computed tomography (CT) at 1, 3 and 6 months post-RFA, and every 6 months thereafter. Patient outcome was evaluated and the tumor recurrence, survival and complications were assessed. Statistical Analysis Used: Discrete categorical data were presented as n (%) and continuous data as mean ± SD. Pearson correlation coefficient was used to determine the relationship between the different variables. Kaplan-Meier survival curve and Log-rank test were used to test the significance of difference between the survival time of the different groups. Results: The ablation success rate was 80.5% (33/41 HCC lesions). 12.2% (5/41) of the lesions were managed with repeat RFA due to tumor residue. 4.9% (2/41) of the lesions were managed with repeated RFA and transarterial chemoembolization. Eight patients had tumor recurrence (five patients (16.1%) had local recurrence and three patients (9.6%) had distant recurrence). Eleven patients died within 3.5-20 months post-RFA. The survival rate at 1 year in patients who completed at least 1 year of follow-up was 63.3%. There was one major complication (1/31, 3.2%) in a patient with a subcapsular lesion and ascites. This patient developed hemoperitoneum in the immediate postprocedure period and was managed with endovascular treatment. She, however, had hepatic decompensation and died 48 h post-RFA. Conclusion: RFA is an effective and safe treatment for small unresectable HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|